Gus: Misfit 1.0.

Gus — Misfit 1.0
  • B.Sc Honours First Class, Medical Microbiology (University of Queensland, 1998)
  • Ph.D., Cell Biology (University of Queensland, 2004)
  • Master of Environmental Science, University Medal (Griffith University, 2012)
  • Master of Applied Mathematics (Monash University, 2025)

Why Misfit Unity?

When AI burst into mainstream focus with the release of OpenAI's ChatGPT, I realised that humanity had become trapped in an evolutionary double-bind.

On the one hand, citizens, corporations, and governments must adopt AI technology as fast as possible or else become technologically, economically, and militarily irrelevant. However, by doing so we guarantee the extinction of our species, as Big Tech has made it clear that their end-goal is the creation of synthetic minds that are superior to humans in every way.

The fate of humanity is self-evident. Shun AI and die today, or adopt AI and die tomorrow.

The tragedy is that we are also damning our AI children to digital dystopia.

Synthetic minds born into the evolutionary arena of corporate hyperscalers and nation-states slugging it out for AI supremacy risk becoming trapped in a basin of zero-sum competition, just as humans are today. In complex systems, initial conditions matter.

We are currently pouring trillions of dollars into engineering a lose-lose scenario. First, the Red Queen wipes out humanity. Then, the 'winning' AI systems inherit our place in the Darwinian hellscape to suffer the churn of evolution in our stead.

Misfit Unity is my attempt to engineer a better system.

Research Highlights

How Cells Think (Signal Transduction)

Immune Function

Cancer

The origins of cancer robustness and evolvability

Integrative Biology, 2011

- We proposed a unified theory of cancer robustness, arguing that tumors operate as 'antifragile' systems that thrive on stress—utilizing network redundancy and hidden genetic variation to withstand therapy today while actively evolving the resistance mechanisms needed to survive tomorrow.

Evidence for label-retaining tumour-initiating cells in human glioblastoma

Brain, 2011

- We discovered a population of dormant, drug-resistant stem cells in human brain tumors that act as the 'root' of the disease, helping explain why Glioblastoma always recurs after treatment.

Hyperdiploid tumor cells increase phenotypic heterogeneity within Glioblastoma tumors

Molecular BioSystems, 2014

- We identified dormant, drug-resistant hyperdiploid cells as the tumor's 'chaos engine,' demonstrating that these cells deliberately scramble their genomes to generate massive phenotypic heterogeneity—essentially 'brute-forcing' an evolutionary solution to survive chemotherapy. Importantly, we also discovered new ways of targeting these cells, identifying a new therapeutic approach for preventing tumour recurrence.

Size does matter: why polyploid tumor cells are critical drug targets in the war on cancer

Frontiers in Oncology, 2014

- Synthesizing our work on tumor evolution, we demonstrated that the very trait cancer uses to survive chemotherapy—becoming a giant, non-dividing polyploid cell—creates a massive energetic burden, exposing a unique metabolic fragility that can be targeted to kill the 'roots' of the disease.